News | October 08, 2009

First Enrollments Made in MADIT-RIT Trial to Find Best ICD/CRT Programming

October 8, 2009 – Boston Scientific Corp. this week announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial, which will determine the best device programming strategy to minimize unnecessary therapy in patients with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) and have no history of cardiac arrest.

The three previous landmark trials, MADIT, MADIT II and MADIT-CRT, each were conducted under the leadership of principal investigator Arthur J. Moss, M.D., professor of medicine at the University of Rochester. The MADIT-RIT trial is a prospective, randomized study that will enroll 1,500 patients at approximately 75 centers globally.

"Clinical science has proved time and again that ICDs are highly effective in reducing death due to arrhythmias in high-risk cardiac patients," said Dr. Moss. "However, some patients receive unnecessary therapy, partly due to the programming of these devices at implant. MADIT-RIT will study the effects of programming on the occurrence of unnecessary therapy in these patients."

The first enrollments in this worldwide trial occurred last month in Graz, Austria at the Medizinische Universitatsklinik Graz (Burkert M. Pieske, M.D., and Daniel Scherr, M.D.); Basel, Switzerland at the Universitatsspital Basel (Beat Schaer, M.D., and Christian Sticherling, M.D.); Detroit, Mich., at the St. John Hospital and Medical Center (Luis Pires, M.D.); and Little Rock, Ark., at Arkansas Cardiology (Steven Greer, M.D.).

For more information: www.bostonscientific.com

Related Content

Cook Medical Launches 2.6 Fr CXI Support Catheter
Technology | Catheters | August 23, 2019
August 23, 2019 — Cook Medical recently released the second generation of the 2.6 Fr CXI...
Biocardia Receives FDA Clearance for Avance Steerable Introducer Family
Technology | Catheters | May 16, 2019
BioCardia Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Avance steerable introducer...
Navitian Coronary Microcatheter Receives CE Mark Approval
News | Catheters | February 21, 2019
Navitian, the new coronary microcatheter from iVascular, recently received CE mark approval. The device was approved to...
First U.S. Patients Treated With OrbusNeich Teleport Microcatheter
News | Catheters | January 31, 2019
Cardiovascular Systems Inc. announced that the first patients in the United States were treated using the OrbusNeich...
Merit Medical Acquires Assets of Vascular Insights LLC
News | Catheters | December 18, 2018
Merit Medical Systems Inc. announced that it has acquired substantially all of the assets of Vascular Insights LLC,...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters | October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters | August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters | March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters | November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters | July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
Overlay Init